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Abstract
Background: The clinic-pathological features and outcomes of Chinese patients with antineutrophil cytoplasmic
autoantibody (ANCA)-positive eosinophilic granulomatosis with polyangiitis (EGPA) and renal involvement have
not been studied.
Methods: Fourteen EGPA patients with renal involvement were included. All patients underwent renal biopsy.
Clinic-pathological features and outcomes were retrospectively analyzed.
Results: The most common initial symptom of EGPA was asthma (57.1 %), followed by hemoptysis (21.4 %),
gross hematuria (14.3 %), and arthritis (7.1 %). All patients had positive serum ANCA (anti-MPO in 12, anti-PR3 in 2).
Elevated eosinophils (median 15 %, range 10–45 %) were found in all patients. The median serum IgE level was
463 g/L (range 200–1000 g/L). All patients presented with renal dysfunction, with a median SCr of 5.4 mg/dL
(range 1.47–11 mg/dL), seven patients (50 %) required initial renal replacement therapy. Thirteen patients showed
hematuria and proteinuria (median 1.1 g/24 h, range 0.5–7.8 g/24 h). Renal biopsy showed pauci-immune segmental
necrotizing glomerulonephritis with crescents in 13 patients and acute interstitial nephritis in one patient. Twelve
patients (85.7 %) showed renal interstitial eosinophil infiltration, among whom three had eosinophilic granuloma.
Among seven patients (71.4 %) who required initial dialysis, 5 discontinued dialysis, one died, one received
maintenance dialysis after glucocorticoids plus immunosuppressive for induction treatment. Twelve patients were
followed up for a median of 43.5 months (range 6–83 months), during follow-up, two patients progressed to
end-stage renal disease, nine had chronic kidney disease with eGFR < 60 mL/min, and two patients had normal eGFR.
Conclusions: Renal involvement in ANCA-positive EGPA could be severe and showed varied renal histology.
Although intensive immunosuppressive therapy effectively improved the renal function, the long-term renal
survival was poor. Early diagnosis and treatment are essential to improve long-term renal survival.
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Background
Eosinophilic granulomatosis with polyangiitis (EGPA),
previously termed Churg–Strauss syndrome [1], is a rare
vasculitis disease, characterized by asthma, eosinophilia,
and systemic vasculitis. EGPA is categorized as an anti-
neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV), but only 35–40 % of EGPA patients are
reported to be ANCA positive, mostly are MPO-ANCA
positive [2, 3].
Renal disease has been reported in 25–45 % of EGPA
[4, 5], with a higher incidence of renal involvement
among ANCA-positive patients. Renal manifestations of
the disease were diverse, most patients had mild urinary
abnormalities [1, 6], whereas some presented with
severe, rapidly progressive glomerulonephritis requiring
dialysis [5]. Renal damage was reported to be more
severe among ANCA-positive EGPA patients [5, 7]. The
typical histopathological lesion was pauci-immune focal
segmental necrotizing glomerulonephritis with crescent
formation. However, other histological lesions have been
reported, and eosinophilic interstitial infiltrates have
been described [5]. The reported long-term renal sur-
vival of EGPA was variable. Most studies reported that
renal function generally remained stable, whereas some
studies reported that a proportion of patients progressed
to ESRD, but all were reported European countries [8, 9].
In this study, we retrospectively analyzed the clinic-




Patients with EGPA were identified from AAV in the
National Clinical Research Center of Kidney Diseases,
Jinling Hospital, from January 1998 to December 2012.
All patients met four or more of the following diagnostic
criteria for EGPA, as proposed by the American
Rheumatism Association in 1990 [10]: (1) asthma; (2)
peripheral blood eosinophils > 10 %; (3) mononeuritis
(including multiplex) or polyneuropathy; (4) nonfixed
pulmonary infiltrates on roentgenography; (5) parana-
sal sinusitis; and (6) extravascular eosinophils proven
histologically. All patients had renal involvement, and
underwent renal biopsy.
Clinical and laboratory data
Clinical measurement included age at disease onset,
duration of EGPA, initial symptoms and organ involve-
ment, red blood cell count of the urinary sediment,
24 h urinary protein excretion, and serum creatinine
(SCr). Serum ANCA and anti-glomerular basement
membrane antibody were detected by both indirect
immunofluoresence and enzyme-linked immunosorbent
assay. The estimated glomerular filtration rate (eGFR)
was estimated by the Chronic Kidney Disease Epidemi-
ology Collaboration equation [11].
Nephrotic syndrome was defined as proteinuria ≥ 3.5 g/
24 h and serum albumin < 30 g/L. Rapidly progressive
glomerulonephritis was defined as massive hematuria,
ccompanied by a rapidly progressive decline in renal
function. Chronic kidney disease (CKD) was defined as
eGFR < 60 mL/min/1.73 m2 lasting for more than
3 months and stages of CKD were defined according to
eGFR as Stage 3: eGFR 30–59 mL/min/1.73 m2, Stage 4:
eGFR 15–29 mL/min/1.73 m2, or Stage 5 (ESRD): eGFR <
15 mL/min/1.73 m2 lasted for at least 3 months [12].
Renal histology
Renal biopsy samples obtained from all patients were
examined with light microscopy, immunofluorescence,
and electronic microscopy. Renal tissues were routinely
stained with hematoxylin and eosin, PAS, and PASM-
Masson for light microscopy. Frozen sections were used
for immunofluorescence. For electron microscopy, tissue
samples were stained with sodium acetate and lead
citrate and examined with a transmission electron
microscope. Glomerular histology was categorized into
four classes: focal (≥50 % normal glomeruli), crescentic
(≥50 % glomeruli with cellular crescents), mixed (<50 %
normal, <50 % crescentic, and <50 % globally sclerotic
glomeruli), and sclerotic (≥50 % globally sclerotic glom-
eruli) [13]. Extensive foot process effacement was defined
as an area of podocyte foot process effacement larger than
50 % of the capillary loop by electron microscopy.
Treatment
Induction therapy included glucocorticoids, glucocorti-
coids plus mycophenolate mofetil (MMF,1–1.5 g/d), or
intravenous cyclophosphamide pulse (IV-CTX) as previ-
ously reported [14]. For patients with severe renal damage
or pulmonary hemorrhage received intravenous methyl-
prednisolone (500 mg/d for 3–6d) pulse therapy and
additional immunoadsorption, followed by oral prednis-
one (started at 0.6 mg/kg/d for 4 weeks, then reduced
gradually to a maintenance dosage of 10 mg/d) [15].
Maintenance therapy included prednisone (10 mg/d)
plus azathioprine (AZA,50–100 mg/d) or Tripterygium
wilfordii polyglycoside (TW, a Chinese herbal medicine;
60 mg/d) [16].
Statistical analysis
Data are presented as mean ± SD or median (range).
Statistical analysis was performed with SPSS 16.0 statis-
tical package (SPSS Inc., Chicago, IL, USA).
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Results
Patient data
The 14 EGPA patients accounted for 5.0 % of the 282
Chinese AAV patients in our department during the
study period. Eight were female and six were male, with
a median age of 53 years (range 20–70 years), duration
of EGPA 120 months (range 1–600 months) and duration
of renal involvement 1.0 month (range 0.5–36 months).
The duration between EGPA and renal involvement was
119 months (range 0–598 months) (Table 1). Prior to the
admission, 12 patients received no glucocorticoids or
immunosuppressive agents, two patients (Cases 4 and 9)
received low-dose glucocorticoids.
Laboratory measurements
All 14 patients were serum ANCA positive, twelve were
P-/MPO-ANCA, with MPO-ANCA levels of 20–674.64
RU/ml, two were C-/PR3-ANCA.
All patients had elevated eosinophils in the peripheral
blood (median 15 %, range 10–45 %) and elevated serum
IgE level (median 463 g/L, range 200–1000 g/L). Eleven
patients (78.6 %) presented with anemia (Table 1).
Onset of symptoms
Eight patients (57.1 %) presented with asthma as the ini-
tial symptom, asthma were mostly paroxysmal, only one
patient presented with persistent asthma. The median
interval between the onset of asthma and systemic vas-
culitis was 239 months (range119–598 months). The
remaining six patients initially presented with symptoms
of systemic vasculitis, including hemoptysis (n = 3), gross
hematuria (n = 2), and arthritis (n = 1) (Tables 1 and 3).
Extra-renal manifestations
The lungs were the most common extra-renal organ
involved, with pulmonary hemorrhage in six patients
(42.9 %), interstitial lung disease in four (28.6 %), and
pulmonary nodules in one (7.1 %). The upper respiratory
tract was the second common involved. Other organ
involvement included the skin, peripheral nerves, joints,
ears, and eyes (Table 2).
Renal manifestations
Twelve patients (85.7 %) presented with rapidly progres-
sive glomerulonephritis and two with CKD. All patients
but one had both hematuria and proteinuria (Table 1).
Urine protein ranged from 0.5–7.8 g/24 h (median 1.1 g/
24 h). Five patients (35 %) presented with nephrotic
syndrome, and two patients had gross hematuria. All
patients had renal dysfunction, with a median SCr level
of 5.4 mg/dl (range1.47–11.0 mg/dl) and a median eGFR
of 9.8 mL/min/1.73 m2 (range 3.5–52.2 mL/min/1.73 m2),
seven patients (50 %) initially required dialysis.
Thirteen renal biopsies showed pauci-immune seg-
mental necrotizing glomerulonephritis, and one biopsy
(Case 2) showed acute interstitial nephritis with normal
glomeruli. Thirteen biopsies (92.8 %) showed glomerular
crescents with the median crescents 39 % (range 9–90 %).
Ten patients (71.4 %) showed glomerular segmental
necrosis. The median glomerular sclerotic ratio was 26 %
(range 0–80 %). Twelve patients (85.7 %) had renal
































1 F/45-55 240/4 Asthma N/NS 1.00 20 358 4.50 45.2 674.6 Mixed 39 49 +b NA
2 F/25-35 24/24 Hemoptysis L/A/SK/N 0.10 45 217 1.47 32.4 343.5 AIN 0 0 + NA
3 F/18-25 1/1 GH N 7.80 16 976 11.00 27 20.0 Crescentic 90 0 + Extensive
4 F/55-65 600/28 Asthma L/H/NS 0.97 31 1000 1.70 43.2 28.8 Mixed 40 27 + NA
5 M/25-35 120/1 Asthma L 1.14 10 316 1.68 41.7 86.3 Focal 19 25 − Segmental
6 F/45-55 408/48 Asthma L/SK 0.99 12 1000 5.90 34 161.0 Mixed 31 45 + NA
7 M/65-75 120/1 Asthma L 4.96 20 580 4.90 29 352.6 Crescentic 51 19 + Extensive
8 F/55-65 2/1 Hemoptysis L 0.50 10 200 10.50 34 180.0 Crescentic 80 0 + Segmental
9 M/45-55 9/1 Arthritis L/SK/A/N/E 0.53 21 287 9.40 37 156.4a Mixed 9 41 − NA
10 M/25-35 36/36 GH N 12.30 14 1000 3.90 28.2 109.5a Mixed 46 42 + Extensive
11 M/55-65 240/1 Asthma L/NS/N 0.50 20 567 6.09 29 101.5 Focal 16 16 +b NA
12 F/45-55 600/2 Asthma L/N 5.32 11 243 2.74 26.5 222.0 Mixed 23 30.8 − NA
13 M/45-55 1/1 Hemoptysis L/H 1.78 13 271 8.68 33.2 207.3 Sclerotic 10 80 + Segmental
14 F/45-55 240/1 Asthma L 4.45 14 567 6.50 25.3 384.8 Crescentic 79 21 +b NA
EGPA eosinophilic granulomatosis with polyangiitis. T1 total duration, T2 duration of renal involvement, EOS eosinophilia, GS glomerular sclerosis, FPE foot
process effacement, GH gross hematuria, SK skin, E eye, N sinusitis, A arthralgia, NS nervous system, L lung, H heart, AIN acute interstitial nephritis, aPR3-ANCA,
beosinophilic granuloma, NA unavailable
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interstitial eosinophilic infiltration, three of whom showed
renal interstitial eosinophilic granuloma. Renal histologic
classification included crescentic type in four, mixed in
six, focal in two, and sclerotic in one. Six biopsies were
evaluated with electron microscopy, and three of the
patients with nephrotic syndrome showed extensive
foot process effacement (Table 3).
Treatment and outcomes
Induction treatment included glucocorticoids plus MMF
regimen (n = 6) or IV-CTX regimen (n = 4), or glucocorti-
coids alone (n = 4; Cases 11 and 12 were complicated with
pneumonia on admission, Case 13 was sclerotic type and
case 14 died at 2 weeks of treatment). Twelve patients
were given methylprednisolone pulse therapy; five pa-
tients received additional immunoadsorption therapy.
During induction period, five of seven patients (71.4 %)
who needed initial dialysis were able to discontinue dia-
lysis, three of them received the MMF regimen, one
received the IV-CTX regimen and one received gluco-
corticoids alone. One patient (Case 13) required main-
tenance dialysis, and the other one (Case 14) died of
cardiac arrhythmia at 2 weeks.
Maintenance therapy included glucocorticoids com-
bined with AZA (n = 6), TW (n = 5) or glucocorticoids
alone (n = 1) (Table 3). The other 12 patients were
follow-up for a median of 43.5 months (range 6–83
months). At last visit, two patients (14.2 %) had normal
renal function, nine (64.3 %) were CKD stage 3–4 with
a mean SCr of 2.13 ± 0.03 mg/dl (range 1.58–2.45) and
eGFR (20.3–39.8 mL/min/1.73 m2), and one patient
(Case 10) progressed to ESRD.
None of the five patients who needed initial dialysis
and were able to discontinue it progressed to ESRD
during 46–63 months (mean 52.4 ± 7.0 months) follow-
up. At last visit, the median SCr was 1.21–2.30 mg/dL
with an eGFR of 24.7–64.4 mL/min/1.73 m2.
During the follow-up, serum ANCA turned negative
in four patients, declined in eight patients. One patient
(Case 2) relapsed with hemoptysis, skin rash, and
eosinophilia, which were concurrent with increased serum
ANCA level in the 25th month of follow-up. No patient
died during maintenance treatment.
Table 2 Extra-renal involvement in patients with EGPA
Extra-renal involvement N (%)
General symptom, n (%) 6 (42.9 %)
Upper respiratory tract, n (%) 8 (57.1 %)
Lung, n (%) 11 (78.6 %)
Hemorrhage, n (%) 6 (42.9 %)
Interstitial pneumonia, n (%) 4 (28.6 %)
Nodules, n (%) 1 (7.1 %)
Skin purpura, n (%) 3 (21.4 %)
Peripheral neuropathy, n (%) 3 (21.4 %)
Arthragia, n (%) 2 (14.3 %)
Heart, n (%) 1 (7.1 %)
Iridocyclitis, n (%) 1 (7.1 %)
EGPA eosinophilic granulomatosis with polyangiitis
Table 3 Treatment and follow-up of patients with EGPA
Case Treatment Follow-up
(months)
Measurements at last visit
Induction Maintenance Hb (g/dl) EOS (%) Upro (g/24 h) SCr (mg/dl) MPO-ANCA (RU/ml)
1 MP/CTX (6ga) Aza 8 11.4 5 0.50 1.58 320
2 MP/CTX (5.8 g) Aza 83 13.4 6 0.10 0.56 0
3 MP/CTX (6 g) Aza 63 13.0 2 2.04 1.21 0
4 Pred/CTX (6.4 g) TW 26 13.7 2 1.02 2.46 0
5 Pred/MMF Aza 28 12.1 2 0.75 2.19 31.8
6 IA/MP/MMF Aza 56 11.1 3 0.14 2.26 63.3
7 IA/MP/MMF Aza 41 11.4 0 1.86 2.41 21
8 IA/MP/MMF TW 46 12.8 3 0.12 1.79 135
9 MP/MMF TW 50 13.7 1 0.2 2.30 89.9
10 MP/MMF Pred 6 6.6 14 0.72 MHD 82.5
11 MP/Pred TW 47 14.0 2 0.45 1.83 0
12 MP/Pred TW 12 12.6 0 1.83 2.40 156
13 IA/MP/Pred Pred 5 10.0 1 1.38 MHD 133.7
14b IA/MP - 0 - - - - -
EGPA eosinophilic granulomatosis with polyangiitis, MHD maintenance hemodialysis Pred prednisone, MP methylprednisolone, Pred prednisone, CTX
cyclophosphamide, MMF mycophenolate mofetil, IA immunoadsorption, TW Tripterygium wilfordii polyglycoside, AZA azathioprine. atotal dose of CTX,
bthe patient died
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Discussion
EGPA, the incidence was reported to be 0.5–6.8 patients
per million per year [8, 9], accounted for 12.2–21.4 % of
AAV in European countries [17, 18]. EGPA accounted
for 5.0 % of patients with AAV in this study, which was
consistent with a report from Japan, but was lower than
that reported in European studies [19].
Typical EGPA presented with three stages [20]: the
allergic stage (characterized by prodromal symptoms of
asthma and anaphylactic rhinitis), the eosinophilic stage
(marked by hypereosinophilia and eosinophilic infiltra-
tion in tissues), and the vasculitic stage (with systematic
vasculitis). The patients in European studies were reported
to have typical allergic disease; the incidence of asthma in
those studies was as high as 96–100 % [9, 21]. Among our
patients, only 57.1 % had a history of asthma or other
allergic symptoms prior to the onset of vasculitis. The
reported incidence of asthma among EGPA patients in
Japan is 72.7–89 % [19, 22]. Hence, the reported inci-
dence of asthma among patients with EGPA is lower in
Asian populations than in European countries, a differ-
ence that might result from racial and geographic differ-
ences. In our study, vasculitis arose without prodromal
allergic symptoms in 42.8 % of the patients, suggesting
rapid disease progression. In fact, no significant asso-
ciation has been found between allergic disease and
EGPA severity [21, 23, 24].
Previous studies [1, 6, 8] found that the renal involve-
ment in EGPA is usually mild with a benign course,
which is an important difference between EGPA and
other types of AAV. Chumbley and colleagues [7] re-
ported that six of 30 EGPA patients had isolated micro-
scopic hematuria, and three had slightly increased SCr.
Lanham et al. [8] reported that among 16 EGPA patients,
only four had renal involvement. However, in recent years,
several studies [2, 5, 25] found that EGPA patients with
positive serum ANCA had severe renal damage. Sinico
et al. [5] reported that among 30 EGPA patients who
presented with rapidly progressive glomerulonephritis,
75 % were ANCA positive, and 50 % had renal dysfunc-
tion. Clutterbuck et al. [25] found that 87 % of EGPA
patients had renal dysfunction and 18.6 % had neph-
rotic syndrome; four patients had SCr levels exceeding
500 μmol/L. Compared with previous reports, the renal
damage of patients in our study was more severe; all
patients had renal dysfunction and half required dialy-
sis. Moreover, 35.7 % of patients had nephrotic syn-
drome, and the percentage of glomeruli with crescent
lesions was high, with a mean of 38 %. It was unclear
whether the difference in severity of renal involvement
in our study versus others was associated with positive
serum ANCA or with racial differences.
Lanham et al. [8] described the histological features of
EGPA as eosinophilic tissue infiltration, extravascular
granulomatosis, and necrotizing vasculitis [1, 6]. The
former two histological findings were thought to differ-
entiate EGPA from other types of AAV. However, it was
reported that these specific lesions rarely existed simul-
taneously. In the present study, only three patients had
all three of these lesions, but the proportion of eosino-
philic infiltration and eosinophilic granuloma in the
renal interstitium were higher in our study than in
other reports [5, 25], consistent with increased eosino-
phils and IgE levels in the peripheral blood. This find-
ing indicates that these pathological changes are not
uncommon in the active stage of the disease, which is
the key clue to the diagnosis of EGPA. We also found
one patient who had only interstitial nephritis without
glomerular involvement. Similar cases have been reported
in the literature [5, 17, 26]. In addition, other renal dis-
eases, such as IgA nephropathy [15] and focal segmental
glomerulosclerosis [27], have also been reported, suggest-
ing that the renal damage of EGPA can vary. Moreover,
five patients had massive proteinuria, which was a higher
percentage than that in previous reports [5, 25]. Electron
microscopy showed extensive podocyte foot process
fusion, which is characteristic of podocyte disease. Park
et al. [27] reported the case of an EGPA patient with
massive proteinuria, whose renal histology showed focal
segmental glomerulosclerosis. This finding indicates
that EGPA can also cause podocyte disease by undefined
pathogenesis.
Immunosuppressive treatment could improve the renal
function of EGPA [28, 29]. In this study, five of seven pa-
tients were able to discontinue dialysis. After immuno-
suppressive therapy with glucocorticoids combined with
either MMF or IV-CTX, SCr levels returned to normal in
one patient who needed initial renal replacement therapy.
The currently recommended regimen is glucocorticoids
combined with IV-CTX as induction therapy. However,
the IV-CTX regimen had substantial adverse effects and
relapses are frequent [30]. Although MYCYC [31], a ran-
domized controlled study compared the efficacy of MMF
and IV-CTX regimens, was unable to demonstrate that
MMF was non-inferior to IV-CTX in induction therapy
for AAV. Our previous study found that MMF was effec-
tive in inducing remission and improving renal function
in Chinese patients with microscopic polyangiitis (MPA)
[14], suggesting that MMF may have therapeutic potential
in Chinese MPA patients. Other small sample, non-
controlled studies also showed that MMF was effective in
inducing remission in patients with AAV [32–35], indicat-
ing that glucocorticoids plus MMF might be an alternative
regimen for the treatment of AAV. Because EGPA is a rare
disease and no large-scale, randomized controlled trials
for treatment. Despite the distinct differences in clinical
character and pathogenesis among MPA, granulomatosis
with polyangiitis and EGPA, the treatment regimens for
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these AAV are not different and the patients have been
uniformly treated according to disease stage and severity.
Both IV-CTX and MMF were effective in the treatment of
EGPA in this study; however, given the small sample size
of this study, the difference in treatment response between
the two regimens was only observational.
During the follow-up period, only two patients had
renal function return to normal; nine patients developed
Stage 3–4CKD and two progressed to Stage 5 CKD. The
long-term renal survival in this study was lower than
that reported in other studies [5, 25, 36]. The study of
the French Vasculitis Study Group demonstrated that
SCr ≥140 μmol/L and proteinuria ≥1 g/d were risk fac-
tors for poor renal prognosis in EGPA. In the present
study, 64.3 % of patients had both of the above risk
factors. Moreover, the high proportion of glomerular
crescents and sclerosis, severe renal interstitial fibrosis,
and old age seen in our patients were all considered
to be poor renal prognosis [28, 29]. In addition,
IMPROVE study [37] found that MMF was less effect-
ive than AZA for maintaining remission and glucocor-
ticoids combined with AZA has been recommended
as the maintenance therapy for AAV. But in this study,
only half of the patients were given AZA as maintenance
therapy, the dosage of AZA was also lower than that
recommended by EULAR [38], which may be associ-
ated with the increased risk of renal relapse and low
renal survival rate.
This study has several limitations. First, all patients
were Chinese, so the results of this study might not
apply to other populations. Second, all patients were
ANCA positive, we did not compare the difference
between ANCA-positive and ANCA-negative EGPA.
Third, sample size was small and the conclusions need
further investigation. Forth, for a retrospective study,
the treatment regimens and the dosage of the immuno-
suppressive agents were not uniform. These factors may
affect our assessments of the clinical features, renal
outcomes and treatment efficacy for patients with EGPA.
Conclusions
Renal involvement in ANCA-positive Chinese EGPA
patients could be severe, and long-term renal survival
was poor in this study. Intensive immunosuppressive
therapy effectively improves renal function, therefore,
early diagnosis and treatment are essential to improve
long-term renal survival.
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